Close Menu

NEW YORK – Co-Diagnostics' joint manufacturing venture, CoSara Diagnostics, has received regulatory clearance from the Central Drug Standard Control Organization in India for five in vitro diagnostic tests.

The five tests are molecular diagnostic assay kits, branded CoSara Saragene, are for the detection of tuberculosis, malaria, hepatitis B and hepatitis C viruses, and human papillomavirus. They can now be manufactured and sold from the CoSara facility in Ranoli, India.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.

Apr
13
Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Apr
15
Sponsored by
Combinati

Detection and quantification of SARS-CoV-2 levels in wastewater can be a useful predictor of potential COVID-19 outbreaks. However, the interpretation of the surveillance data can be challenging.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).